A citation-based method for searching scientific literature


List of co-cited articles
970 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



10-year follow-up of intensive glucose control in type 2 diabetes.
Rury R Holman, Sanjoy K Paul, M Angelyn Bethel, David R Matthews, H Andrew W Neil. N Engl J Med 2008
33


Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.
Jeffrey A Johnson, Sumit R Majumdar, Scot H Simpson, Ellen L Toth. Diabetes Care 2002
287
32

Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study.
Tina Ken Schramm, Gunnar Hilmar Gislason, Allan Vaag, Jeppe Nørgaard Rasmussen, Fredrik Folke, Morten Lock Hansen, Emil Loldrup Fosbøl, Lars Køber, Mette Lykke Norgaard, Mette Madsen,[...]. Eur Heart J 2011
268
31

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
30

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Anushka Patel, Stephen MacMahon, John Chalmers, Bruce Neal, Laurent Billot, Mark Woodward, Michel Marre, Mark Cooper, Paul Glasziou, Diederick Grobbee,[...]. N Engl J Med 2008
29

Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer,[...]. N Engl J Med 2013
28


Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
24

Effects of intensive glucose lowering in type 2 diabetes.
Hertzel C Gerstein, Michael E Miller, Robert P Byington, David C Goff, J Thomas Bigger, John B Buse, William C Cushman, Saul Genuth, Faramarz Ismail-Beigi, Richard H Grimm,[...]. N Engl J Med 2008
23

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
John A Dormandy, Bernard Charbonnel, David J A Eckland, Erland Erdmann, Massimo Massi-Benedetti, Ian K Moules, Allan M Skene, Meng H Tan, Pierre J Lefèbvre, Gordon D Murray,[...]. Lancet 2005
22

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Steven E Kahn, Steven M Haffner, Mark A Heise, William H Herman, Rury R Holman, Nigel P Jones, Barbara G Kravitz, John M Lachin, M Colleen O'Neill, Bernard Zinman,[...]. N Engl J Med 2006
21

Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis.
K M Pantalone, M W Kattan, C Yu, B J Wells, S Arrigain, A Jain, A Atreja, R S Zimmerman. Diabetes Obes Metab 2012
77
27

Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
Ioanna Tzoulaki, Mariam Molokhia, Vasa Curcin, Mark P Little, Christopher J Millett, Anthea Ng, Robert I Hughes, Kamlesh Khunti, Martin R Wilkins, Azeem Majeed,[...]. BMJ 2009
309
20

Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study.
Christianne L Roumie, Adriana M Hung, Robert A Greevy, Carlos G Grijalva, Xulei Liu, Harvey J Murff, Tom A Elasy, Marie R Griffin. Ann Intern Med 2012
194
20

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Jennifer B Green, M Angelyn Bethel, Paul W Armstrong, John B Buse, Samuel S Engel, Jyotsna Garg, Robert Josse, Keith D Kaufman, Joerg Koglin, Scott Korn,[...]. N Engl J Med 2015
20


Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Silvio E Inzucchi, Richard M Bergenstal, John B Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L Peters, Apostolos Tsapas, Richard Wender, David R Matthews. Diabetes Care 2012
18

Glucose control and vascular complications in veterans with type 2 diabetes.
William Duckworth, Carlos Abraira, Thomas Moritz, Domenic Reda, Nicholas Emanuele, Peter D Reaven, Franklin J Zieve, Jennifer Marks, Stephen N Davis, Rodney Hayward,[...]. N Engl J Med 2009
18

Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease.
Jie Hong, Yifei Zhang, Shenghan Lai, Ankang Lv, Qing Su, Yan Dong, Zhiguang Zhou, Weili Tang, Jiajun Zhao, Lianqun Cui,[...]. Diabetes Care 2013
196
18

Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus.
Adriaan Kooy, Jolien de Jager, Philippe Lehert, Daniël Bets, Michiel G Wulffelé, Ab J M Donker, Coen D A Stehouwer. Arch Intern Med 2009
246
17


Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
17

Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial.
Julio Rosenstock, Nikolaus Marx, Steven E Kahn, Bernard Zinman, John J Kastelein, John M Lachin, Erich Bluhmki, Sanjay Patel, Odd-Erik Johansen, Hans-Jürgen Woerle. Diab Vasc Dis Res 2013
112
14

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.
Philip D Home, Stuart J Pocock, Henning Beck-Nielsen, Paula S Curtis, Ramon Gomis, Markolf Hanefeld, Nigel P Jones, Michel Komajda, John J V McMurray. Lancet 2009
924
14

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
14



Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Marc A Pfeffer, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Lars V Køber, Francesca C Lawson, Lin Ping, Xiaodan Wei, Eldrin F Lewis,[...]. N Engl J Med 2015
13


Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme.
Odd Erik Johansen, Dietmar Neubacher, Maximilian von Eynatten, Sanjay Patel, Hans-Juergen Woerle. Cardiovasc Diabetol 2012
168
12

Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention--a retrospective nationwide cohort study.
Casper H Jørgensen, Gunnar H Gislason, Charlotte Andersson, Ole Ahlehoff, Mette Charlot, Tina K Schramm, Allan Vaag, Steen Z Abildstrøm, Christian Torp-Pedersen, Peter R Hansen. Cardiovasc Diabetol 2010
47
25

Cardiovascular outcomes in trials of oral diabetes medications: a systematic review.
Elizabeth Selvin, Shari Bolen, Hsin-Chieh Yeh, Crystal Wiley, Lisa M Wilson, Spyridon S Marinopoulos, Leonard Feldman, Jason Vassy, Renee Wilson, Eric B Bass,[...]. Arch Intern Med 2008
216
12

Metformin use and mortality among patients with diabetes and atherothrombosis.
Ronan Roussel, Florence Travert, Blandine Pasquet, Peter W F Wilson, Sidney C Smith, Shinya Goto, Philippe Ravaud, Michel Marre, Avi Porath, Deepak L Bhatt,[...]. Arch Intern Med 2010
241
12

Improved clinical outcomes associated with metformin in patients with diabetes and heart failure.
Dean T Eurich, Sumit R Majumdar, Finlay A McAlister, Ross T Tsuyuki, Jeffrey A Johnson. Diabetes Care 2005
272
12


Basal insulin and cardiovascular and other outcomes in dysglycemia.
Hertzel C Gerstein, Jackie Bosch, Gilles R Dagenais, Rafael Díaz, Hyejung Jung, Aldo P Maggioni, Janice Pogue, Jeffrey Probstfield, Ambady Ramachandran, Matthew C Riddle,[...]. N Engl J Med 2012
988
12

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.
N Sarwar, P Gao, S R Kondapally Seshasai, R Gobin, S Kaptoge, E Di Angelantonio, E Ingelsson, D A Lawlor, E Selvin, M Stampfer,[...]. Lancet 2010
12


The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis.
Kevin M Pantalone, Michael W Kattan, Changhong Yu, Brian J Wells, Susana Arrigain, Anil Jain, Ashish Atreja, Robert S Zimmerman. Diabetes Care 2010
58
18

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
Jean-Louis Chiasson, Robert G Josse, Ramon Gomis, Markolf Hanefeld, Avraham Karasik, Markku Laakso. JAMA 2003
11

Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study.
Scot H Simpson, Sumit R Majumdar, Ross T Tsuyuki, Dean T Eurich, Jeffrey A Johnson. CMAJ 2006
160
11

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.
Silvio E Inzucchi, Richard M Bergenstal, John B Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L Peters, Apostolos Tsapas, Richard Wender, David R Matthews. Diabetes Care 2015
11

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
11

Severe hypoglycemia and risks of vascular events and death.
Sophia Zoungas, Anushka Patel, John Chalmers, Bastiaan E de Galan, Qiang Li, Laurent Billot, Mark Woodward, Toshiharu Ninomiya, Bruce Neal, Stephen MacMahon,[...]. N Engl J Med 2010
929
10

Effect of a multifactorial intervention on mortality in type 2 diabetes.
Peter Gaede, Henrik Lund-Andersen, Hans-Henrik Parving, Oluf Pedersen. N Engl J Med 2008
10

Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction.
Marianne Zeller, Nicolas Danchin, Dominique Simon, Alec Vahanian, Luc Lorgis, Yves Cottin, Jacques Berland, Pascal Gueret, Pascal Wyart, Régis Deturck,[...]. J Clin Endocrinol Metab 2010
81
12

The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
Kevin M Pantalone, Michael W Kattan, Changhong Yu, Brian J Wells, Susana Arrigain, Anil Jain, Ashish Atreja, Robert S Zimmerman. Acta Diabetol 2009
94
10



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.